patients must participate in their
formation so that they address the
issues that matter most to them in an
efficient and sustainable manner.”
Ong MK, Romano PS, Edgington S, et al.
JAMA Intern Med. 2016;doi:10.1001/jamainternmed.2015.7712.
Periodontitis
Increases Risk
of a First MI
infarction (MI), according to a study
published in Circulation.
The PAROKRANK study (periodontitis and its relation to coronary artery disease), a multicenter case-control Swedish
study, was conducted in 805 patients
(ages < 75 years) with a first myocardial infarction (MI) and 805 age (mean
Patients with periodontitis are at
greater risk for a first myocardial
Chronic Angina may
be holding him back
For patients limiting their activity due to
chronic angina, adding Ranexa® may help
In the CARISA Trial1
Ranexa 1000 mg BID,* when added to a beta-blocker
or calcium channel blocker,† was superior to those
treatments plus placebo at:
Increasing exercise duration (24 secs change vs placebo from
baseline at Week 12)
Increasing the time to onset of ischemia during exercise
testing at peak plasma concentrations (94 vs 59 secs)
Decreasing angina frequency (2.1 vs 3.3 avg/wk)
Decreasing nitroglycerin use (1.8 vs 3.1 avg doses/wk)
Learn how Ranexa may help your patients get back on track
www.RanexaHCP.com/CSWN
BID = twice daily
*Limit the dose of Ranexa to 500 mg BID when coadministered with diltiazem, verapamil, or other moderate
CYP3A inhibitors.
†
CARISA TRIAL DESIGN1: CARISA (Combination Assessment of Ranolazine In Stable Angina) was a doubleblind, randomized, placebo-controlled clinical trial of 823 patients with chronic angina who received Ranexa
750 mg BID (n = 272), Ranexa 1000 mg BID (n = 261), or placebo (n = 258) for 12 weeks (note, 750 mg is not
an approved dose). At the physician’s discretion, patients received either atenolol 50 mg, amlodipine 5 mg,
or diltiazem 180 mg once daily as requ